Provided herein are ERFE fusion polypeptides, compositions and methods of use for treatment, for example in treatment of iron metabolism disorders.

The invention relates to a method for selecting a glycopolypeptide that binds to a target protein, the method including the steps of providing a pool of glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex; combining the pool with a target protein to form a mixture; incubating the mixture for a period of time sufficient to allow any target protein to bind to one or more of the glycopolypeptides, thereby forming glycopolypeptide-target protein complexes; and isolating from the mixture the glycopolypeptide-target protein complexes, thereby identifying a plurality of selected glycopolypeptides.

The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

This disclosure relates generally to modified SARS-CoV-2 spike polypeptides. More particularly, the present disclosure relates to modified SARS-CoV-2 spike proteins with improved properties, to chimeric polypeptides comprising these modified proteins, and to complexes comprising the chimeric polypeptides. The present disclosure also relates to the use of these modified polypeptides, chimeric polypeptides and complexes in compositions and methods for eliciting an immune response to ACE2-interacting coronaviruses, including SARS-CoV-2, and/or for treating or inhibiting the development of ACE2-interacting coronaviruses infections.

Disclosed are engineered corticotropin-releasing factor (CRF) antagonist agents, including engineered corticotropin-releasing factor (CRF) binding agents. The CRF antagonist agents and binding agents can be used to neutralize excess CRF in vivo and comprise a polypeptide having CRF-specific binding activity under physiological conditions coupled to one or more half-life-extending moieties. Pharmaceutical compositions are disclosed containing the CRF binding agents, which can be used in methods of treatment for diseases, disorders, or conditions involving hypothalamic pituitary adrenal (HPA) axis hyperactivity. Also disclosed are engineered nucleic acids (e.g., expression constructs or vectors) encoding the CRF binding agents and recombinant host cells comprising the engineered nucleic acids.

Provided herein are glycosylated ComP proteins, fragments and fusion proteins thereof, and methods of making, for example, for use in the production of conjugate vaccines. Also provided herein are conjugate vaccines against diseases including bacterial diseases.

Disclosed are components, systems, and methods for glycoprotein or recombinant glycoprotein protein synthesis in vitro and in vivo. In particular, the present invention relates to components, systems, and methods for identifying amino acid glycosylation tag motifs for N-glycosyltransferases and the use of the identified amino acid glycosylation tag motifs in methods for preparing glycoproteins and recombinant glycoproteins in vitro and in vivo.

Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R), wherein IL2 or IL2R comprises at least one fewer glycosylation site compared to native IL2 or native IL2R. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.